Tri Deca (3 Nandrolone esters)

01 Overview

Tri-Deca  300mg/ml 2ml  c/u 5 vials

02 Details

Tri Deca

 (3 Nandrolone esters)

Decanoato de nandrolona, Nandrolon-dekanoát, Nandrolone, décanoate de, Nandroloni decanoas, Nandrolonu dekanonian, Nortestosterone Decanoate, Nortestosterone Decylate, 3-Oxoestr-4-en-17β-yl decanoate, 17β-Hydroxyestr-4-en-3-one decanoate, Нандролона Деканоат, Nortestosterone Decylate

 

 

C28H44O3 = 428.6.

CAS — 360-70-3.

ATC — A14AB01; S01XA11.

ATC Vet — QA14AB01; QS01XA11.

Pharmacopoeias. In Eur.(see p.vii) and US.

Tri-Deca contains: 300mg

  • 100 mg / ml Nandrolone decanoate
  • 100 mg / ml Nandrolone phenylpropionate
  • 100 mg / ml Nandrolone undecanoate

 

Pharmacologic Category

Androgen

Uses and Dosing

Anabolic agents have been used for reversing catabolic conditions, promoting weight  gain, increasing muscling, and stimulating erythropoiesis

Mechanism of action

Nandrolone decanoate, Nandrolone phenylpropionate and Nandrolone undecanoate are injectable forms of nandrolone. They have a similar mechanism of action of all androgenic anabolic steroids.

Duration

Nandrolone decanoate provides a spike in nandrolone release 24-48 hours (mean, 30 hours) following deep intramuscular injection, which steadily declines to near baseline levels approximately two weeks later.

The median half-life of nandrolone decanoate is 8 days (5-16)

Nandrolone phenylpropionate provides a sharp spike in nandrolone release 24-48 hours following deep intramuscular injection, and declines to near baseline levels within a week.

Nandrolone undecanoate is designed to provide a slow release of nandrolone for up to 3 to 4 weeks following injection.

Administration

Deep intramuscular

Protein binding

Moderate

Bioavailability

73% in gluteal muscle

Time to peak in blood

24-48 hours for nandrolone decanoate and nandrolone undecanoate

Storage/Stability

 

Store in a tightly sealed container, protected from light, and at room temperature.

Stability of compounded formulations has not been evaluated.

 

Contraindications

Hypersensitivity to the drug, prostate cancer, male breast cancer, breast carcinoma in women with hypercalcemia, CPI, severe atherosclerosis, nephrotic syndrome, acute and chronic liver disease, including alcoholic nephritis, pregnancy, lactation.

Pregnancy Risk Factor

X

Category X: Studies in animals or human beings have demonstrated fetal abnormalities, or there is evidence of fetal risk based on human experience, or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.

 

Pregnancy Considerations

Use is contraindicated in women who are or may become pregnant; masculinization of the fetus has been reported.

Lactation

Excretion in breast milk unknown/not recommended

Breast-Feeding Considerations

It is not known if nandrolone is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.
Adverse Effects and Precautions

– Estrogenic: low tendency for estrogen conversion, 20% of that seen with testosterone (in comparison). Elevated estrogen levels may appear with high doses, and may cause side effects such as water retention, increased body fat and gynecomastia.

– Androgenic: side effects especially with higher doses. This may include oily skin, acne and body or facial hair growth. Anabolic steroids may also aggravate hair loss. Women are warned of the potential virilizing effects of anabolic steroids. Nandrolone is a steroid with relatively low androgenic activity.

– Hepatotoxicity: Nandrolone is not c-17 alpha alkylated, and not known to have hepatotoxic effects in healthy subjects. Liver toxicity has not been reported yet in medical literature.

– Cardiovascular:  As other anabolic steroids, a marked decrease in HDL and increase in LDL is characteristic, increasing cardiovascular risk is a non-quantifiable level.

– Testosterone Suppression: All androgenic steroids when taken in doses sufficient to promote muscle mass gain are expected to suppress endogenous testosterone production. Studies using 100 mg per week of nandrolone for six weeks have demonstrated an approximate 50% reduction in serum testosterone levels during therapy. At a dosage of 300 mg per week, this reduction reached 70%. Prolonged hypogonadotrophic hypogonadism can develop secondary to steroid abuse, necessitating medical intervention.

 

Interactions

Interactions reported include: Glucocorticoids, mineralocorticoids, corticotropin preparations containing sodium rich foods enhances sodium retention in the body, increase the risk of developing edema, acne eruptions intensify.

Increases the action of antiplatelet, anticoagulant, insulin and oral antidiabetics, decreases action somatotropin and its derivatives.
Dosage forms

Nandrolone decanoate; oily injectable solution: 50 mg, 200 mg or 300 mg.

 

Pharmacodynamics/Kinetics

Following intramuscular dose of 100 mg peak plasma concentration is achieved over 1-3 weeks.

Metabolism: Hepatic (Liver)

Elimination: Urine (90%) and Feces (6%)
The decanoate ester provides a slow from the place of injection, lasting up to three weeks. Exhibits relatively strong anabolic properties, however, its tissue-building activity is accompanied by weak androgenic properties. This has to do with the reduction of nandrolone to a weaker steroid, dihydronandrolone, in the same androgen-responsive target tissues.

Nandrolone is usually given as the decanoate ester in the form of oily intramuscular injections. The hexyloxyphenylpropionate, propionate, phenylpropionate, and undecylate esters have also been used.

There are currently 3 ongoing trials of nandrolone decanoate in humans, one of them assessing its usefulness in telomeropathies (rare congenital diseases). Another study in severely burned patients, and a third one assessing the metabolism and doping analysis in healthy individuals

These trials were found through a search in the United States and Europe clinical trial databases.

In animal studies, nandrolone helped regulating muscle repair in rats.

 

Administration in Men:

The usual dosage for performance-enhancing purposes of nandrolone decanoate is 200-600 mg per week, taken in cycles 8 to 12 weeks in length. It is often stated that nandrolone decanoate will exhibit its optimal effect (best gain/side effect ratio) at 2 mg per pound of bodyweight/weekly.

 

The usual dosing for nandrolone phenylpropionate is 200-400mg per week in cycles of 8-12 weeks (divided in two administrations per week).

 

The usual dosing for nandrolone undecanoate is 200 to 300mg per week in cycles of 8-12 week but doses up to 400-600mg per week have been used for bulking and cutting purposes.

 

 

Administration in Women:

 

When using nandrolone  for performance-enhancing purposes, 50 mg per week taken for 4-6 weeks is an usual dose. Although only slightly androgenic, women are occasionally confronted with virilization symptoms when taking this compound. Studies have demonstrated high tolerability (minor but statistically insignificant incidence of virilizing side effects) with a dose of 100 mg every other week for 12 weeks.

 

The usual dosing for performance-enhancing purposes of nandrolone undecanoate in women is  80mg every 10 days for 4 to 6 weeks.

 

The usual dosing for performance-enhancing purposes of nandrolone penylpropionate in women is 50mg per week for 4 to 6 weeks.